First-in-class phosphate absorption inhibitor approved by FDA
European Pharmaceutical Review
OCTOBER 18, 2023
The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. XPHOZAH is expected to be available to eligible patients in the US in November 2023.
Let's personalize your content